Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Recipient : Immuron
Deal Size : Undisclosed
Deal Type : Agreement
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
Details : The Phase II clinical trial will evaluate the efficacy of a single dose regimen of Travelan® in a controlled human infection model (CHIM) using the enterotoxigenic Escherichia coli (ETEC) strain H10407.
Product Name : Travelan
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
April 10, 2022
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Recipient : Immuron
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SGN1
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Sinogen Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 02, 2021
Lead Product(s) : SGN1
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Sinogen Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLX703A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : OliX Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg).
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
October 20, 2021
Lead Product(s) : OLX703A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : OliX Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement